Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (20547)	5/11/1998 10:33:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< Any predictions on how the street will view this tomorrow??? >> Hey, you know what? Let's say for instance, that the higher volume accumulation, over the last week or so, was in preparation, in part, for this announcement. If true, then the market is already telling us that it likes it, by the accumulation of shares, prior to the announcement. It could be, right?! I'm hoping that is true. So, I'm hoping to see over 750,000 shares traded and up about 1/2 to $14.50. The next leg up could come from the earnings report and then the NDA. What does the winner win? The one with the closest guess gets what? Regards, Bob

To: John O'Neill who wrote (20547)	5/12/1998 7:11:00 AM
From: Henry Niman	Respond to of 32384

JO, I think that the response will be positive, but the significance may not be appreciated for a few weeks. The situation is somewhat like the GLYC acquisition in the spring of 1995. LGND was trading in the $6-$7 range and within a few months they were into double digits (and they set their all time high of 19 3/4 within a year). The move picked up some new shareholders and put LGND on the radar screen. MTSL and CTSL put LGND in their portfolios and Bear Stearns initiated coverage. I think that LGND will get more coverage very soon and an NDA filing (for topical Panretin) coupled with FDA approval (for ONTAK), will generate enthusiasm from more conservative analysts and shareholders who have been watching from the sidelines.